OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors Apr 24, 2019 8:00am EDT
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer Apr 23, 2019 8:00am EDT
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center Apr 17, 2019 8:00am EDT
OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress Apr 08, 2019 8:00am EDT
OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting Apr 02, 2019 8:00am EDT
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma Apr 01, 2019 8:00am EDT
